Introduction
Heparin-induced thrombocytopenia (HIT) is an immunologic adverse response to heparin therapy. HIT usually results in a platelet count decrease of more than 50% and often a new thrombosis, typically occurring a couple of days after the start of the prophylactic or therapeutic dose of heparin. Antibodies associated with HIT are often directed to platelet factor 4 (PF4) bound to heparin. Large immune complexes of these IgG antibodies cross-link platelets and trigger platelet activation. The observed thrombocytopenia is caused by this intravascular platelet activation. The activated platelets form the catalytic surface for thrombin generation leading to thrombosis.
NODIA offers both immunological assays from Hyphen BioMed and functional assays from 5-Diagnostics:
Our partner Hyphen BioMed offers ZYMUTEST™ HIA, a standardized ELISA method, optimized for the detection of heparin-dependent antibodies in human plasma, serum or other biological fluid, allowing confirmation of the HIT diagnosis or its clinical suspicion.
Vaccine-induced prothrombotic immune thrombocytopenia in COVID-19
The HYPHEN BioMed ZYMUTEST™ HIA Mono Strip, IgG is an enzyme immunoassay that is suitable for the detection of antibodies involved in Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) after COVID-19 vaccination. It has appropriate sensitivity for all pathophysiologically relevant antibodies. (source)
ZYMUTEST™ HIA
– Immunological assay –
Introduction
ELISA method for the detection of heparin dependent antibodies. A new concept for the diagnosis of Heparin Induced Thrombocytopenia.
Major Features
- Better correlation with clinical context
- Captures not only Ab’s against PF4, but also against NAP2 and IL8
- Binds circulating heparin-protein-AB complexes
- Detects both Heparin and Protamine Sulphate antibodies
Products
On Demand
Reaction principle
Microplates are coated with both functionally available Heparin and Protamine Sulphate.
- Binds chemokines present in the sample and forms auto-antigen that captures the heparin dependent antibodies.
- Can fix heparin-protein-antibody complexes generated in the blood circulation.
- Enhanced sensitivity and specificity by addition of cell lysate: Brings a source of proteins like Platelet Factor 4 (PF4), Interleukin-8 (IL8) and Neutrophil-Activating Peptide-2 (NAP-2) which are known to be antigenic in complex with heparin.
- Screening with IgGAM mixture or by specific testing with IgG-, IgM- or IgA- antibodies.
